A detailed history of Callan Capital, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Callan Capital, LLC holds 5,299 shares of GILD stock, worth $466,735. This represents 0.03% of its overall portfolio holdings.

Number of Shares
5,299
Previous 5,299 -0.0%
Holding current value
$466,735
Previous $363,000 -0.0%
% of portfolio
0.03%
Previous 0.03%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$63.15 - $72.88 $38,395 - $44,311
608 Added 12.96%
5,299 $363,000
Q1 2024

Oct 22, 2024

SELL
$71.58 - $87.29 $43,520 - $53,072
-608 Reduced 11.47%
4,691 $343,000
Q1 2024

May 03, 2024

BUY
$71.58 - $87.29 $4,437 - $5,411
62 Added 1.34%
4,691 $343,000
Q4 2023

Feb 02, 2024

BUY
$73.27 - $83.09 $339,166 - $384,623
4,629 New
4,629 $374,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Callan Capital, LLC Portfolio

Follow Callan Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Callan Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Callan Capital, LLC with notifications on news.